The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The past decade in oncology has been marked by the rise of immunotherapy, which leverages the immune system to attack tumors. For many solid tumors, immune checkpoint inhibitors have supplanted ...

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't ...

Immunoengineering, which has been beneficial to other medical specialties, could be used in the infectious diseases field to ...

How do antibody engineers select isotypes? IgG1 has been the most popular choice by far and was used for 13 approved chimeric, humanized or fully human antibodies (compared with only two instances ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates, and ...

However, there is an important limitation of the currently reported single chain antibody used as a chimeric antigen receptor (CAR) targeting domain. Specifically, CAR aggregation leads to CAR-T ...

a fully human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully human antiTNF-a monoclonal antibody; Pemazyre ...

Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

Major players operating in the carvykti market are Johnson & Johnson Services Inc., Legend Biotech, and Novartis AG. North America was the largest region in the carvykti market in 2024. Asia-Pacific ...

The Phase 1 trial, fully funded by a U.S. Department of Defense grant awarded to Cleveland Clinic, is nearing enrollment completion. Monitoring and data analysis will continue over the next three to ...